Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Ulcerative Colitis

In brief

The purpose of this study is to determine whether low dose Asacol® (27 mg/kg - 71 mg/kg) and high dose Asacol® (53 mg/kg - 118 mg/kg) are safe and effective when dosed as 400 mg delayed-release tablets given twice daily for 26 weeks to children and adolescents for the maintenance of remission of ulcerative colitis.

Key facts

Study ID: NCT01004185
Run by: Warner Chilcott
People needed: 39
Starts: 2009-10-01
Expected to finish: 2011-03-01
Last updated by the study team: 2012-05-25

Who can join

Age: 5 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

male or female between the ages of 5 and 17 years, inclusive, at the time of the first dose of study medication;
have a documented history of UC that has been successfully maintained in complete remission for at least 1 month prior to study entry
have a baseline PUCAI score < 10
have a body weight no less than 17 kg and no more than 90 kg
have a history of at least 1 active episode or relapse in the last 12 months
have taken a stable maintenance dose of oral mesalamine (or equivalent oral 5-ASA dose) for at least 1 month prior to entry in the study. Stable is defined as the same dose for the last month.
maintained complete remission, as defined, throughout the 30-day run-in phase. Note:ONLY applies to those patients who complete the 6-week treatment in complete remission from Study 2007017 and immediately roll-over to the 30-day run-in phase
are female patients who are pre-menarchal or have a negative urine pregnancy test and, if sexually active, practice acceptable contraception (e.g., abstinence; oral, intramuscular, or implanted hormonal contraception [at least 3 months prior to enrollment]

You may not qualify if…

have a history of allergy or hypersensitivity to salicylates, aminosalicylates, or any component of the Asacol tablet
have a significant co-existing illness or other condition(s), including but not limited to cancer or significant organic or psychiatric disease on medical history or physical examination, that, in the judgment of the Investigator, contraindicate(s) administration of the study drug and/or any study procedures
have a history or presence of any condition causing malabsorption or an effect on gastrointestinal motility or history of extensive small bowel resection (greater than one half the length of the small intestine) causing short bowel syndrome
any "condition" causing "malabsorption" or an effect on gastrointestinal "motility"
have current renal disease, or a screening blood urea nitrogen (BUN) or creatinine value that is > 1.5 times the upper limit of the age appropriate normal
have a documented history of or current hepatic disease, or liver function tests (alanine transaminase [ALT], aspartate transaminase [AST], total bilirubin) that are > 2 times the upper limit of normal
have a history of pancreatitis
have undergone treatment with any oral, intravenous, intramuscular, or rectally administered corticosteroids (including budesonide) within 30 days prior to the Screening visit
have undergone treatment with any rectal mesalamine therapy within 30 days prior to the screening visit
have undergone treatment with immunomodulatory therapy including, but not limited to: rosiglitazone, 6-mercaptopurine or azathioprine, cyclosporine, or methotrexate within 90 days prior to Screening visit
have undergone treatment with biologic therapy including, but not limited to: infliximab,adalimumab, certolizumab or other biologic treatment of ulcerative colitis within 90 days prior to Screening visit
have undergone treatment with antibiotics (other than topical antibiotics) including metronidazole within 7 days prior to the Screening visit
have undergone treatment with aspirin or other nonsteroidal anti-inflammatory drugs NSAIDs) within 7 days prior to the Screening visit
have undergone treatment with any antidiarrheals and/or antispasmodics within 30 days of the Screening visit
have a stool examination positive for Clostridium difficile (C. difficile), bacterial pathogens, or ova and parasites. Note: Because normal gut flora may vary by geography, the Medical Monitor should be consulted before excluding a patient with a stool sample that is positive for C. difficile, bacterial pathogens or ova and parasites.

Where it is running

Research Site — Phoenix, Arizona, United States
Research Site — Loma Linda, California, United States
Research Site — San Diego, California, United States
Research Site — San Francisco, California, United States
Research Site — San Francisco, California, United States
Research Site — Gainesville, Florida, United States
Research Site — Miami, Florida, United States
Research Site — Park Ridge, Illinois, United States
Research Site — Louisville, Kentucky, United States
Research Site — Portland, Maine, United States
Research Site — Boston, Massachusetts, United States
Research Site — Worcester, Massachusetts, United States
Research Site — Southfield, Michigan, United States
Research Site — Jackson, Mississippi, United States
Research Site — Kansas City, Missouri, United States
Research Site — Las Vegas, Nevada, United States
Research Site — Mays Landing, New Jersey, United States
Research Site — Buffalo, New York, United States
Research Site — New Hyde Park, New York, United States
Research Site — Providence, Rhode Island, United States
Research Site — Nashville, Tennessee, United States
Research Site — Fort Worth, Texas, United States
Research Site — San Antonio, Texas, United States
Research Site — Huntington, West Virginia, United States
Research Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.